Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeLymphoblastic Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Positron Emission Tomography
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT06918431
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
- Conditions
- Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionOther: Informational InterventionBehavioral: Compliance MonitoringOther: Media InterventionOther: Health Promotion and EducationOther: Medical Device Usage and EvaluationOther: Questionnaire AdministrationBehavioral: Training and EducationBehavioral: Telephone-Based Intervention
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 64
- Registration Number
- NCT06639958
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Kaiser Permanente-Oakland, Oakland, California, United States
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Lymphoblastic LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-05
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Ma-Spore ALL 2020 Study
- Conditions
- B Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Target Recruit Count
- 27
- Registration Number
- NCT06279767
- Locations
- 🇨🇳
Department of Neurosurgery of The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- Conditions
- T Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanBiological: NavitoclaxProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
- Conditions
- Myelodysplastic Syndromes, AdultAcute Myeloid Leukemia, Adult
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06199557
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.